What is Asceneuron?
Founded in 2012 and headquartered in Lausanne, Switzerland, Asceneuron is dedicated to discovering and developing novel small molecules designed to halt and prevent the molecular events that drive neurodegeneration. The company targets high unmet medical needs in orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to bring transformative treatments to patients suffering from these debilitating conditions. Asceneuron's scientific approach focuses on key pathological pathways, positioning it as a key player in the competitive landscape of neurodegenerative disease research and development.
How much funding has Asceneuron raised?
Asceneuron has raised a total of $130.6M across 2 funding rounds:
Series A
$30.6M
Series C
$100M
Series A (2015): $30.6M with participation from Sofinnova Partners, Kurma Partners, MS Ventures, and SR One
Series C (2024): $100M led by SR One, Novo Holdings, and OrbiMed
Key Investors in Asceneuron
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. They are a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in investing at various maturity stages. They transform disruptive scientific discoveries into advanced medical solutions.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics. They partner with founders and scientific teams to translate innovative technologies into new medicines.
What's next for Asceneuron?
The recent major strategic investment signals a pivotal growth phase for Asceneuron, likely enabling the acceleration of its clinical development pipeline and the expansion of its research initiatives. This infusion of capital is expected to support the advancement of its lead drug candidates through late-stage trials and potentially towards regulatory submission. The company's focus on addressing severe neurological disorders, coupled with substantial financial backing, suggests a strategic trajectory aimed at achieving significant milestones in therapeutic innovation and market penetration within the biotechnology sector.
See full Asceneuron company page
